PURPOSE: In the United States, adjuvant radiation therapy is currently recommended for most patients with rectal cancer. We conducted this population-based study to evaluate the rate of radiation therapy and the factors affecting its delivery. METHODS: We used the Surveillance Epidemiology and End Results database to assess treatment of patients with nonmetastatic rectal cancer diagnosed over a 25-year period (1976 through 2000). We evaluated the rate of radiation therapy use and its timing (preoperative vs. postoperative) and the influence of factors such as tumor stage and grade; patient gender and race; and geographic location. RESULTS: In this 25-year period, 45,627 patients met our selection criteria. The rate of radiation therapy use increased dramatically over time: from 17 percent of advanced-stage patients in 1976 to 65 percent in 2000 (P < 0.0001). Until 1996, the increase was due almost entirely to postoperative radiation therapy. Since 1996, the rate of preoperative radiation therapy use has increased (P < 0.0001) and the rate of postoperative radiation therapy use has begun to decline. We found, after controlling for the year of diagnosis, that female patients, African Americans, older patients, and patients with low-grade lesions were less likely to undergo radiation therapy (P < 0.0001). Geographic location was also an important predictor of radiation therapy use. CONCLUSIONS: The use of radiation therapy for patients with rectal cancer has dramatically increased over the 25-year period studied, with a recent shift to the use of preoperative radiation therapy; however, in 2000, over 30 percent of patients with advanced-stage nonmetastatic rectal cancer did not undergo radiation therapy. Given the variation in radiation therapy use that we found to be due to demographic factors, access to adjuvant radiation therapy can be improved.
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MATERIALS AND METHODS

Data
We used data from the Surveillance Epidemiology and End Results (SEER) cancer registry to conduct this study. SEER, a population-based registry sponsored by the National Cancer Institute, collects information on cancer incidence and survival from 11 populationbased cancer registries and 3 supplemental registries; these 14 registries include approximately 14 percent of the U.S. population. 12 
Patients
We included patients age 18 or older who were diagnosed with adenocarcinoma of the rectum from January 1976 through December 2000. Excluded from our study were patients who had in situ or metastatic disease, patients with malignancies other than adenocarcinoma, and patients who did not undergo some form of surgical therapy.
Analysis
We determined the overall rate of radiation, preoperative radiation, and postoperative radiation. We evaluated the effect of demographic, surgical, and tumor factors on radiation and determined time trends. We compared means using the Wilcoxon rank-sum test and proportions using the chi-squared test. We used the Cochran-Armitage trend test on one degree of freedom to determine whether rates had changed over time. We used logistic regression to test the associations between radiation and age, race, gender, year of diagnosis, tumor grade, tumor stage, surgical treatment, and geographic location by registry. We limited the logistic regression to patients diagnosed from 1988 through 2000, such that only patients with available AJCC staging were included. Our analysis was limited to patients for whom radiation is routinely recommended (AJCC Stage II and III patients).
Our study used preexisting data with no personal identifiers, and was thus exempt from review by the University of Minnesota's Institutional Review Board.
RESULTS
A total of 45,627 patients in our 25-year study period were diagnosed with rectal cancer and met our selection criteria. In 99 percent of these patients (n = 45,000), radiation status could be determined. Of these patients 14,571 (32 percent) underwent radiation therapy (Table 1) . Patients who underwent radiation therapy tended to be younger (median age, 65) than those who did not undergo radiation therapy (median age, 70) (P < 0.0001). They were more likely to be male (61 percent male, radiation therapy, vs. 55 percent male, no radiation therapy; P < 0.0001). Patients who underwent radiation therapy were also more likely to have regional spread (64 percent) than those who did not undergo radiation therapy (29 percent) (P < 0.0001). In addition, patients who underwent radiation therapy were more likely to have also undergone radical excision as part of treatment (90 percent) than those who did not undergo radiation therapy (73 percent) (P < 0.0001). Of note, detailed surgical information has only been available in SEER since 1983. Before adjustment for other factors, African Americans were slightly more likely to receive radiation (35 percent) than non-African Americans (32 percent) (P < 0.0003). However African Americans were also more likely to have regional disease (47 percent of those with known stage) than non-African Americans (42 percent of those with known stage) (P < 0.00001).
The frequency of radiation therapy use for patients The increase in radiation therapy use was due almost entirely to postoperative radiation therapy use until 1996. Since that time, the rate of preoperative radiation therapy use has significantly increased (P < 0.0001) and the rate of postoperative radiation has actually begun to decline (Fig. 2) . Of note, we found significant staging differences for patients who underwent preoperative radiation vs. those who underwent postoperative radiation. Patients who underwent pre- operative (vs. postoperative) radiation were more likely to be missing stage information (18 percent vs. 2 percent; P < 0.0001); they were also more likely to have localized disease (38 percent vs. 26 percent; P < 0.0001). Conversely, patients who underwent preoperative (vs. postoperative) radiation were less likely to have regional spread (44 percent vs. 72 percent; P < 0.0001).
In our multivariate models, controlling for the year of diagnosis and geographic location by registry, we found that male gender and younger age were predictors of radiation therapy use (P < 0.0001) ( Table 2 ).
African Americans were less likely to undergo radiation therapy (P < 0.003) than patients of other races. Patients with poorly differentiated rectal cancer and those with AJCC Stage III rectal cancer were significantly more likely to undergo radiation therapy than those with well-differentiated or moderately differentiated rectal cancer or with AJCC Stage II cancer (P < 0.0001). In all our multivariate models, the year of diagnosis and geographic location by registry remained important predictors of radiation therapy (P < 0.0001).
DISCUSSION
Our study demonstrates a gradual but persistent increase in adjuvant radiation therapy use for patients with rectal cancer over a 25-year period: from 17 percent in 1976 to 65 percent in 2000 for patients with regional spread. Interestingly, despite the NIH Consensus Conference recommendations in 1990, the rate of radiation therapy use did not dramatically rise after that recommendation. Thus the increase was not in direct response to it. In terms of AJCC staging (available in SEER only since 1988), we found that the rate of radiation therapy use in 2000 was 59 percent for AJCC Stage II patients and 68 percent for AJCC Stage III patients. Although most patients underwent appropriate adjuvant radiation therapy, substantial numbers of patients who might benefit from therapy did not receive it-perhaps more than 7,000 patients in the United States per year (extrapolating from our data to the U.S. population). In many cases, patients may not have undergone radiation therapy because of appropriate medical considerations (e.g., extreme medical comorbidity) or because of their own preference. However, given the variations in adjuvant radiation therapy use that we identified with regard to age, race, gender, and geographic location, and given the considerable change in the rate over time, it is likely that other modifiable factors-such as the underlying practice patterns of individual surgeons or institutions-played an important role.
The overall rate of adjuvant radiation therapy use that we found in 2000 for AJCC Stage II (59 percent) and Stage III patients (68 percent) appears to be higher than the rate found in other population-based studies. Two previous studies used SEER data linked to Medicare data to examine the rate of adjuvant radiation and chemotherapy use in individuals age 65 and older from 1992 through 1996. One of these stud- ies found a rate of radiation use of 51 percent 12 ; the other, 57 percent. 11 Both focused on AJCC Stage II and III patients. But given the influence of older age on radiation therapy use that numerous studies [11] [12] [13] (including ours) have noted, those two studies of individuals age 65 and older do not apply to younger patients. In a similar study evaluating 534 adult patients who developed rectal cancer in 1996 and 1997 while residing in California Cancer Registry regions, the unadjusted rates of adjuvant radiation varied from 82 percent in patients younger than 55 years old to 14 percent in patients at least 85 years of age. It is noteworthy that none of the population-based studies evaluated trends over time. None of the previous studies evaluated trends in preoperative delivery of adjuvant radiation. The National Cancer Data Base (NCDB) 14 reported trends in rectal cancer treatment over time, comparing treatment in 1985-86, 1989-90, and 1994-95 . A much smaller change in the use of adjuvant radiation was seen in this NCDB report: adjuvant radiation therapy use increased from 54 percent in AJCC Stage III patients in the first years studied to 61 percent in the final years studied. The NCDB study was not population based, and its findings in 1994-95 may not be directly comparable to the earlier time periods; the proportion of rectal cancer patients in the United States included in the NCDB increased from 24 percent of all patients in 1985-86 to 53 percent in 1994-95. Hospitals reporting data in the first years of the NCDB study likely had substantially different treatment practices, compared with hospitals recruited to the NCDB in subsequent years or compared with all hospitals in the United States. In addition, the NCDB study did not look at trends in preoperative radiation therapy. Consistent with growing evidence of the effectiveness and superiority of preoperative radiation, [7] [8] [9] 15, 16 our study demonstrates a substantial increase in its use since 1996. In fact, although the overall rate of any adjuvant radiation has continued to increase, since 1996 the rate of postoperative radiation has actually declined. In our study, we noted important differences in staging between patients who underwent preoperative radiation. Patients who underwent preoperative vs. postoperative radiation were more likely to be missing staging information or to have earlystage disease. We are not able to determine whether those differences were caused by a complete pathologic tumor response (which occurs in 10 percent to [17] [18] [19] [20] ; by downstaging because of partial tumor response after radiation; by uncertainty on the part of the person doing the staging as to how to interpret AJCC rules after preoperative therapy; by inadequate nodal evaluation; or by other factors. However, given the increasing rate of preoperative radiation therapy use, researchers using the SEER database in the future must carefully consider its influence on stage distribution in SEER. In fact, because of the effect of preoperative radiation on staging and the increasing frequency in the use of preoperative radiation, stage-specific research using SEER may be difficult or impossible. Our population-based study included large numbers of patients. Yet only limited information on patient and tumor characteristics is available from SEER. Such characteristics, of course, may affect treatment decisions, but we could not control for them in our study. Of note, SEER does not include information on administration of chemotherapy, so we could not evaluate the use of adjuvant chemotherapy in combination with radiation. Because the formal AJCC stage is only available in SEER as of 1988, we could not evaluate radiation trends with regard to AJCC stage for our entire study period. Still, in the final year of our study the rates of adjuvant radiation use were similar in patients with regional spread per SEER (65 percent) and those with AJCC Stage III disease (68 percent). This finding, we believe, justifies our use of SEER staging to evaluate trends.
Despite these limitations, our study demonstrated a dramatic increase in adjuvant radiation use for rectal cancer patients over time and also demonstrated a recent shift from postoperative to preoperative adjuvant radiation therapy. However, even in the final year of our study, we noted that significant numbers of patients who might have benefited from radiation did not undergo it. Given the variations in adjuvant radiation therapy use by patient age at diagnosis, gender, race, and geographic location identified in our study and in others, [11] [12] [13] 21 access to this beneficial and recommended therapy can still be improved. Continued study of treatment trends and of factors influencing them is needed.
